Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107980
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107980
Impact of fibrinogen-to-albumin ratio on the long-term prognosis of patients with advanced HER2-negative gastric cancer receiving immunochemotherapy
Zhi-Yuan Yao, Jie Liu, Xiao Ma, Wan-Ting Li, Yu Shen, Yong-Zheng Cui, Yan Fang, Zheng-Xiang Han, Chun-Hua Yang
Zhi-Yuan Yao, Zheng-Xiang Han, Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China
Jie Liu, Wan-Ting Li, Yu Shen, Yong-Zheng Cui, Chun-Hua Yang, Department of Radiotherapy, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China
Xiao Ma, Department of Oncology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China
Yan Fang, Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou 215000, Jiangsu Province, China
Co-first authors: Zhi-Yuan Yao and Jie Liu.
Co-corresponding authors: Zheng-Xiang Han and Chun-Hua Yang.
Author contributions: Yao ZY, Liu J, Han ZX, and Yang CH contributed to the conceptualization, writing-review and editing of this manuscript; Yao ZY and Yang CH were responsible for the methodology of this study; Yao ZY contributed to the formal analysis of this manuscript and the visualization of this article; Yao ZY, Liu J, Ma X, Li WT and Shen Y took part in the writing-original draft and investigation of this manuscript; Yao ZY, Han ZX and Yang CH contributed to the project administration and the supervision of this manuscript; Liu J, Ma X, Li WT, Shen Y and Fang Y took part in the data curation of this study; Yao ZY and Liu J were responsible for the validation of this manuscript; Shen Y and Cui YZ took part in the resources; Han ZX and Yang CH were involved in the supervision of this study; Yao ZY and Liu J contributed equally to the manuscript, they are co-first authors of this manuscript. Han ZX and Yang CH contributed to this manuscript equally, they are co-corresponding authors of this study.
Institutional review board statement: This research was carried out following the Declaration of Helsinki and received approval from the Ethics Committee at the Affiliated Hospital of Xuzhou Medical University (approval No. XYFY2023-KL277-01).
Informed consent statement: Given the retrospective design of this investigation, the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University granted us an exemption from obtaining written informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data included in this study can be obtained from the corresponding author at 13063518075@126.com.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Hua Yang, MD, PhD, Professor, Department of Radiotherapy, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Xuzhou 221000, Jiangsu Province, China. 13063518075@126.com
Received: April 2, 2025
Revised: April 17, 2025
Accepted: May 13, 2025
Published online: June 15, 2025
Processing time: 72 Days and 23.9 Hours
Core Tip

Core Tip: This study is the first to validate the prognostic value of the fibrinogen-to-albumin ratio (FAR) in advanced HER2-negative gastric cancer patients receiving immunochemotherapy. High FAR was significantly associated with shorter progression-free survival and overall survival, establishing FAR as an independent prognostic factor. The predictive model incorporating FAR allows for personalized survival predictions, offering a valuable and cost-effective tool for clinical decision-making. These findings underscore FAR's potential as a practical biomarker for guiding treatment strategies in advanced gastric cancer.